Call for Abstract

18th International Conference on Medicinal Chemistry & Targeted Drug Delivery and Drug Designing , will be organized around the theme “Scientists Unlock Research― Exploring & Inspiring Innovations in Chemistry, Drug Delivery & Drug Discovery through Modern Pharmaceutical Techniques”

MedChem and TDD 2017, USA is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in MedChem and TDD 2017, USA

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Chemistry is a stimulating field as it links many scientific disciplines and allows for collaboration with other scientists in researching and developing new drugs.

Chemists apply their chemistry training to the process of synthesizing new pharmaceuticals. They also improve the processes by which existing pharmaceuticals are made. Medicinal chemists are focused on drug discovery and development and are concerned with the isolation of medicinal agents found in plants, as well as the creation of new synthetic drug compounds. Most chemists work with a team of scientists from different disciplines, including biologists, toxicologists, pharmacologists, theoretical chemists, microbiologists, and biopharmacists. Together, this team uses sophisticated analytical techniques to synthesize and test new drug products and to develop the most cost-effective and environmentally friendly means of production.

  • Track 5-1Physical Chemistry
  • Track 5-2Food Chemistry
  • Track 5-3Geo-Chemistry

New challenges and opportunities for those engaged in Computer-Aided Drug Design. These challenges require us to move beyond typical application areas and develop new tools and techniques.This conference will focus on many of the new challenges facing drug design, and seek to set new research directions to address these challenges. We will address a number of pertinent topics including:

  • The application of computational methods to the design of biologics
  • Data analysis and visualization techniques to support multi-objective optimization
  • The application of computational methods to drug discovery programs driven on data from phenotypic assays
  • The impact of open source software and open data on drug design
  • The impact of "big data" on drug discovery
  • Computational methods applied to the optimization of binding kinetics

Research in Drug Design encompasses the entire spectrum from Bench to Bedside, with the aim of enabling the delivery of novel, safe, therapeutics to patients, leading to an increase in Health and Well being within the general population. Our multi disciplinary approach draws together world leading researchers from across the globe, coupled with strong collaborations with academic partners and the Pharmaceutical sector. Such partnerships allow us to develop novel approaches to the design and isolation of novel therapeutic agents, their testing within in silico and in vitro models, and ultimately the translation of such research into clinical practice.

 

Current Research

• The development of novel therapeutic agents derived from natural plant products

• The use of '-omic' level measurements, coupled with in silico modelling, to develop systems-level understanding of cellular response to chemical challenge

• Nuclear Receptor Biology and their role in coordinating cellular response to chemical challenge. Special focus on the diseases of aging, including cardiovascular, metabolic and oncology

• The molecular mechanisms of DNA damage repair, with particular emphasis on their role in human degenerative diseases

• Breast, ovarian and prostate cancer research, developing both novel therapeutics and understanding the development of multiple-drug resistance phenotype within these diseases.

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and / or death of nerve cells. This causes problems with movement (called ataxias), or mental functioning (called dementias).

Dementias are responsible for the greatest burden of disease with Alzheimer’s representing approximately 60-70% of cases.

The neurodegenerative diseases that JPND focuses on are:

  • Alzheimer’s disease (AD) and other dementias
  • Parkinson’s disease (PD) and PD-related disorders
  • Prion disease
  • Motor neurone diseases (MND)
  • Huntington’s Disease (HD)
  • Spinocerebellar ataxia (SCA)
  • Spinal muscular atrophy (SMA)

The Forum recognized that in addition to humanitarian reasons for fighting infectious diseases in developing countries, have a self-interest in combating infectious diseases. Pathogens can spread far from where they first developed due to increases in trade, international tourism and climate change. Severe Acute Respiratory Syndrome (SARS) exemplified how an infectious disease may quickly transcend borders, triggering important economic ripple effects globally, even in countries with few cases.

Meeting the cost of scaling-up PDP investments needs to be accompanied by more accurate forecasting of demand for medicines required for neglected diseases, as this would reduce the risk to investors and potential innovators and could create stronger incentives to service these markets. Participants made it clear that many health issues in developing countries cannot and will not be solved by developments in health technologies alone. Nevertheless, such technologies are important and efforts are needed to create the innovation environment that will rapidly deliver new medicines for all types of disease.

A major challenge in medicine and the biomedical sciences today is the problem of antibiotic resistance, the phenomenon by which agents of infectious diseases – bacteria being most relevant to this article – no longer respond to treatment with the ‘miracle drugs’. Let’s understand this phenomenon by tracing the roles of infectious diseases in human history; our approaches to understanding and treating them over millennia; the recent use and abuse of antibiotics and the resultant spread of antibiotic resistance; the antiquity of antibiotics in natural environments and the inevitability of resistance; and the way forward.

This methods used in the synthesis of organic compounds with particular attention to medicinal products and illicit substances. Students are expected to utilize information presented in each module to develop and complete their module assignments. Other activities will include online discussions of course topics and current issues that relate to the synthesis of medicinal products and illicit substances.

It reviews key concepts and principles of those sciences, including:

  • Modern concepts of drug action, drug-receptor interactions, and pharmacophore analysis
  • Molecular basis for the mechanism of action of drugs
  • Concepts in PK and PD, drug efficacy and potency, physiological effects, and structure/function relationships
  • Modern drug design approaches, including structure-based and ligand-based drug design
  • ADME/tox

The design of novel drugs or of improved higher generation therapeutics is a complex task that goes beyond improving the specificity of the drug to its biological target. Since in many cases, only a minute fraction of the administered drug reaches the critical pharmacological target, strategies for increasing the drug's accumulation in the vicinity of the cellular DNA must be devised. Thus, drug delivery strategies should strive to prolong circulation time, enhance tissue-specific accumulation, increase the effectiveness of cellular and nuclear uptake in addition to high specificity and affinity towards the DNA. The complexity of the biological system makes it very difficult to simultaneously incorporate all of these factors into a single algorithm for drug design. Focusing on specificity is relatively straightforward since the structure of the DNA is well known.

In Current Opinion in Chemical Biology, we help the reader by providing in a systematic manner:

1. The views of experts on current advances in chemical biology in a clear and readable form.

2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications.

Division of the subject into sections:

The subject of chemical biology is divided into themed sections which are reviewed regularly to keep them relevant. For 2016 they are:

  • Omics
  • Bioinorganic chemistry
  • Biocatalysis and Biotransformation
  • Next Generation Therapeutics
  • Molecular Imaging
  • Synthetic Biology
  • Synthetic Biomolecules
  • Energy
  • Mechanistic Biology